Brain bleed breakthrough? Two-Drug combo aims to stabilize blood pressure and save lives

NCT ID NCT07695220

Not yet recruiting Disease control Sponsor: The Third Affiliated Hospital of Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates whether giving two drugs—remifentanil and dexmedetomidine—soon after a spontaneous brain hemorrhage can safely lower blood pressure and improve recovery. The study includes adults with a brain bleed who have high blood pressure and are treated within six hours of symptoms starting. Researchers will compare this intensive blood pressure-lowering strategy to standard care, measuring disability and survival at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remifentanil and dexmedetomidine
What this could lead to: If successful, this approach could offer a new, more stable way to control blood pressure after a brain bleed, potentially reducing disability and death.
What could go wrong: This is an early-stage trial, and the combination of drugs may cause side effects like low blood pressure or breathing problems. It is not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACEREBRAL HEMORRHAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.